PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients

Clinical trial NCT02928523 · COMPLETED

Trial details

NCT number: NCT02928523
Sponsor: MaaT Pharma
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia, Myeloid, Acute

Start date: 2016-06-01
Primary completion: 2017-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.